Publicado 4 números por año
ISSN Imprimir: 0731-8898
ISSN En Línea: 2162-6537
Indexed in
Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
SINOPSIS
Lung cancer is responsible for 1.6 million deaths. Approximately 80%−85% of lung cancers are of the non-small-cell variety, which includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma. Knowing the stage of cancer progression is a requisite for determining which management approach−surgery, chemotherapy, radiotherapy, and/or immunotherapy−is optimal. Targeted therapeutic approaches with antiangiogenic monoclonal antibodies or tyrosine kinase inhibitors are one option if tumors harbor oncogene mutations. Another, newer approach is directed against cancer-specific molecules and signaling pathways and thus has more limited nonspecific toxicities. This approach targets the epidermal growth factor receptor (EGFR, HER-1/ErbB1), a receptor tyrosine kinase of the ErbB family, which consists of four closely related receptors: HER-1/ErbB1, HER-2/neu/ErbB2, HER-3/ErbB3, and HER-4/ErbB4. Because EGFR is expressed at high levels on the surface of some cancer cells, it has been recognized as an effective anticancer target. EGFR-targeted therapies include monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors. Tyrosine kinases are an especially important target because they play an important role in the modulation of growth factor signaling. This review highlights various classes of synthetically derived molecules that have been reported in the last few years as potential EGFR-TK inhibitors (TKIs) and their targeted therapies in NSCLC, along with effective strategies for overcoming EGFR-TKI resistance and efforts to develop a novel potent EGFR-TKI as an efficient target of NSCLC treatment in the foreseeable future.
-
Zheng Yuan-Yuan, Xiao Rong, Zhang Lu-Xin, Yan Hui-Jie, Wang Ji-Hong, Lv Li, A Novel Mutant of rLj-RGD3 (rLj-112) Suppressed the Proliferation and Metastasis of B16 Cells through the EGFR Signaling Pathway, Marine Drugs, 17, 2, 2019. Crossref
-
Hoang Tung, Myung Seung-Kwon, Pham Thu Thi, Kim Jeongseon, Ju Woong, Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials, Journal of Clinical Medicine, 9, 4, 2020. Crossref
-
Wang Meng-na, Kuang Yun, Gong Li-ying, Hua Ye, Pei Qi, Guo Cheng-xian, Cao Yu, Huang Jie, Yang Guo-ping, First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects, Investigational New Drugs, 38, 6, 2020. Crossref
-
Yuan Yuan , Wang Yonggang , Liu Zimei , Sun Yong , Yao Yang , Yu Wenxi , Shen Zan , MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen, International Journal of Oncology, 2019. Crossref
-
Zhang Ding, Song Dongli, Shi Lin, Sun Xiaoru, Zheng Yonghua, Zeng Yiming, Wang Xiangdong, Mechanisms of interactions between lung‐origin telocytes and mesenchymal stem cells to treat experimental acute lung injury, Clinical and Translational Medicine, 10, 8, 2020. Crossref
-
Dai Yuemei , Wang Wenran , Sun Qingchao , Tuohayi Jiazina , Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines, Experimental and Therapeutic Medicine, 2018. Crossref
-
Tchelebi Leila T, Batchelder Emma, Wang Ming, Lehrer Eric J, Drabick Joseph J, Sharma Navesh, Machtay Mitchell, Trifiletti Daniel M, Zaorsky Nicholas G, Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies, JNCI Cancer Spectrum, 5, 4, 2021. Crossref
-
Lu Min, Liu Bin, Xiong Hui, Wu Fang, Hu Chunhong, Liu Ping, Trans ‐3,5,4´‐trimethoxystilbene reduced gefitinib resistance in NSCLC s via suppressing MAPK /Akt/Bcl‐2 pathway by upregulation of miR‐345 and miR‐498 , Journal of Cellular and Molecular Medicine, 23, 4, 2019. Crossref
-
Zhang Zhirui, Zhang Mengxiao, Liu Hao, Yin Wu, AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells, Journal of Cellular Biochemistry, 120, 1, 2019. Crossref
-
Ge X, Zhang Y, Huang F, Wu Y, Pang J, Li X, Fan F, Liu H, Li S, EGFR tyrosine kinase inhibitor Almonertinib induces apoptosis and autophagy mediated by reactive oxygen species in non-small cell lung cancer cells, Human & Experimental Toxicology, 40, 12_suppl, 2021. Crossref
-
Wang Jia-li, Chen Chuan-sheng, Jia Zhi-rong, Miao Li-yun, Xie Jun, Pan Zhen-zhen, Duan Ya-lei, Liu Shuo, Hou Meng-jun, Ding Xuan-sheng, Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations, Journal of Cancer Research and Clinical Oncology, 2022. Crossref